Last reviewed · How we verify
NCT06072937: HEARTFUL-CHD
IntelliStent for Pulmonary Flow Adjustment in Congenital Heart Disease and Dilated Cardiomyopathy
NA trial testing IntelliStent in Pulmonary Arterial Hypertension in 10 participants. Not yet recruiting.
4 June 2025
Quick facts
| Lead sponsor | HeartPoint Global |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 4 June 2024 |
| Primary completion | 4 June 2025 |
| Estimated completion | 4 June 2026 |
Drugs / interventions tested
- IntelliStent
Conditions studied
- Pulmonary Arterial Hypertension — all drugs for Pulmonary Arterial Hypertension →
- Dilated Cardiomyopathy — all drugs for Dilated Cardiomyopathy →
- Congenital Heart Disease — all drugs for Congenital Heart Disease →
Sponsor
HeartPoint Global
Who can join
Adults 12 to 60, any sex, with Pulmonary Arterial Hypertension or Dilated Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
IntelliStent is intended to achieve reduction of pulmonary hypertension, improvements in symptoms and quality of life in pediatric, adolescent and adult patients with congenital heart disease associated pulmonary arterial hypertension or left ventricular dilated cardiomyopathy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Innovative Multilumen Stent System for Pulmonary Flow Adjustment in Congenital Heart Disease and Dilated Cardiomyopathy.
Tocchi M, Amin EK, Vogt P, Tkach E, et al · · 2023 · cited 2× · PMID 38093737 · DOI 10.1016/j.jacbts.2023.10.003
Verify or expand the search:
- PubMed search for NCT06072937
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pulmonary Arterial Hypertension
Currently open trials in the same condition.
- NCT07391228 — Cognitive Alterations in Pulmonary Arterial Hypertension (PAH) · active not recruiting
- NCT06351345 — 129 Xenon Imaging in Patients Treated With Sotatercept · Phase 2 · recruiting
- NCT07217522 — Rutgers University Study of the Genetics of Pulmonary Hypertension · recruiting
- NCT07013149 — The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial Hypertension · recruiting
- NCT06658522 — Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effec · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06072937 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by HeartPoint Global
- Last refreshed: 16 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06072937.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing